Bringing the fundamentals into focus…
Back to Lineage Cell Therapeutics, Inc.
How Lineage Cell Therapeutics, Inc. stacks up
LCTX · against 276 other Healthcare companies of similar size
Growth
64/ 100
Above the middle of the pack.
Ranked #88 of 277 · scores higher than 68% of peers
Bars: peers in each 10-point band of the growth score26 peers with a growth score of 60–69, including LCTX · Click a bar to see the companies
Why growth scores 64?
Weighted metrics compared with all Healthcare companies.Mainly thanks to its revenue growth, which is stronger than most Healthcare peers.
- Still loss-making, but the loss per share narrowed. Earnings per share growth: — vs peer median 9.8%
- 3-year revenue growth is close to the peer norm. 3-year revenue growth: 7.5% vs peer median 5.8%
- faster revenue growth over the last year: stronger than 78% of peers. Revenue growth: 19.9% vs peer median 6.1%
Metric by metric
Position: dot = LCTX, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | LCTX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 291 reported | 19.9% | 3.3% | 80% | 33% | |
| Earnings per share growthHigher is better · 125 reported | Not reported | 2.2% | — | — | 33% |
| 3-year revenue growthHigher is better · 269 reported | 7.5% | 3.9% | 63% | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around LCTX| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 464M USD | 100 | 53 | |
| 2 | 1.8B HKD (≈$224M) | 99 | 59 | |
| 2 | 7.2B TWD (≈$224M) | 99 | 41 | |
| 2 | 592M ILS (≈$160M) | 99 | 84 | |
| 2 | 433M USD | 99 | 81 | |
| 84 | 363.6B KRW (≈$262M) | 66 | 55 | |
| 84 | 418M USD | 66 | 74 | |
| 86 | 2.9B CNY (≈$408M) | 65 | 37 | |
| 86 | 5.0B SEK (≈$497M) | 65 | 61 | |
| 88 | 255M USD | 64 | 36 | |
| 89 | 2.9B HKD (≈$365M) | 63 | 84 | |
| 89 | 487M USD | 63 | 24 | |
| 91 | 221M USD | 62 | 33 | |
| 91 | 639M AUD (≈$422M) | 62 | 55 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score